Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Background
- Current treatments
- Photodynamic therapy (PDT)
- Mechanism of action (1)
- Mechanism of action (2)
- Mechanism of action (3)
- Photo chemical internalization (PCI)
- Photosensitizer: Protoporphyrin IX (PpIX)
- Challenging issue of PDT related to PpIX
- History of PDT (1900 - present)
- Proposed solution for issues of PDT
- Significance of the proposed study
- Chosen materials
- 3 proposed aims of study
- Aim I: After Glow NanoParticles (AG NPs)
- Improving the size of NPs
- Surface modification of AG NPs
- Aim I results
- Results (SEM)
- Parameters affecting luminescence intensity (1)
- Parameters affecting luminescence intensity (2)
- Reducing the size of particles
- Luminescence decay & water dispersion of NPs
- Size decrement
- In vitro study: cell viability
- Aim II: solve low solubility of PpIX
- Modification of PpIX
- Folic acid (FA) & Modified PpIX (MPpIX) conjugate
- Aim II: results
- Conjugation efficiency
- Improvement of photo luminescence of MPpIX
- In vitro study: red light emission of modified drug
- Aim III: conjugation of PpIX to AG NPs
- Conjugation of FA to PpIX-conjugated AG NPs
- Preparing the powder form of samples
- Aim III: results
- Characterization: Raman & UV-Vis spectroscopy
- Aim III: conjugation efficiency
- Red emission enhancement of PpIX with AG NPs
- FRET between AG NPs and PpIX
- Water dispersion & red emission of PpIX-AG NPs
- In vitro study: cell viability
- In vitro study: cancer cells exposed to conjugate
- In vitro: adding UV treatment to cells
- Summary
- Acknowledgments
- References
Topics Covered
- Photodynamic therapy (PDT) mechanism of action
- PDT & photosensitizer Protoporphyrin IX (PpIX)
- After Glow NanoParticles (AG NPs)
- Solving low solubility of PpIX
- Conjugation of PpIX to AG NPs
- In vitro study: cell viability, cancer cells and UV treatment
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Homayoni, H. (2015, May 4). Protoporphyrin IX (PpIX)-conjugated self-lighting nanoparticles for photodynamic therapy: synthesis and characterization [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/HFHX9796.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Homa Homayoni has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Protoporphyrin IX (PpIX)-conjugated self-lighting nanoparticles for photodynamic therapy: synthesis and characterization
Published on May 4, 2015
35 min
Other Talks in the Series: Nanomedicine
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, everybody.
My name is Homa.
I'm a post-doc research associate in
the chemical engineering department
at Northeastern University in
Boston where my today talk is going
to cover my PhD thesis which was
about protoporphyrin IX conjugated
self-lighting nanoparticle
for photodynamic therapies
in synthesis and characterization.
This research was done in joint
biomedical engineering program
in the University of Texas
at Arlington and University
of Texas Southwestern
Medical Center in Dallas
under supervision of
Professor Wei Chen
from the Department of Physics
in the University of Texas
at Arlington.
0:45
The reason we focused on
cancer during this research
was that cancer is the
second leading cause
of death in the United States.
Cancer statistics of the
United States in 2010 and 2012
confirm more than one and half a
million new cancer cases, and more
than half a million deaths.
Cancer is a term used
for diseases in which
abnormal cells develop
without control
and are able to
invade other tissues.
Cancer cells can spread
to other parts of the body
through the blood and lymph system.
When a tumor becomes malignant,
then it becomes cancer.
1:26
All available current treatments
unfortunately are suffering
from very bad side effects.
For example, in chemotherapy,
all the drugs have been designed
to kill fast growing cancer cell.
But at the same time,
they are able to kill fast
growing healthy cell,
like those located
in hair, in mouth, in GI tract.
These drugs also are able to affect
a number of white blood cells.
For another exam in
radiation therapy,
radiation is able to
damage DNA of healthy cell
to cause secondary cancer.
So to get rid of all of
these unwanted side effects,
photodynamic therapy has been
introduced as a clinical approach.
And its limitation is only
photosensitivity reaction
and swelling in the treated area.
Hide